文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.

作者信息

Spiegel Jay Y, Dahiya Saurabh, Jain Michael D, Tamaresis John, Nastoupil Loretta J, Jacobs Miriam T, Ghobadi Armin, Lin Yi, Lunning Matthew, Lekakis Lazaros, Reagan Patrick, Oluwole Olalekan, McGuirk Joseph, Deol Abhinav, Goy Andre, Vu Khoan, Andreadis Charalambos, Munoz Javier, Bennani N Nora, Vose Julie M, Dorritie Kathleen A, Neelapu Sattva S, Locke Frederick L, Rapoport Aaron P, Hill Brian T, Miklos David B

机构信息

Stanford University Medical Center, Stanford, CA.

University of Maryland School of Medicine-Greenebaum Comprehensive Cancer Center, Baltimore, MD.

出版信息

Blood. 2021 Apr 1;137(13):1832-1835. doi: 10.1182/blood.2020006245.

DOI:10.1182/blood.2020006245
PMID:33156925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8555382/
Abstract
摘要

相似文献

[1]
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.

Blood. 2021-4-1

[2]
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Blood. 2020-6-4

[3]
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Lancet Oncol. 2018-12-2

[4]
[Successfully treatment with axicabtagene ciloleucel of a female patient with an early relapsed diffuse large B-cell lymphoma].

Recenti Prog Med. 2025-2

[5]
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.

JAMA Oncol. 2020-2-1

[6]
Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.

Oncologist. 2019-10-4

[7]
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.

Int J Radiat Oncol Biol Phys. 2019-6-5

[8]
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.

Clin Lymphoma Myeloma Leuk. 2022-10

[9]
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.

Future Oncol. 2021-4

[10]
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.

Blood Adv. 2025-2-11

引用本文的文献

[1]
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.

J Hematol Oncol. 2025-7-1

[2]
An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.

Cell Transplant. 2025

[3]
Single-cell RNA sequencing in diffuse large B-cell lymphoma: tumor heterogeneity, microenvironment, resistance, and prognostic markers.

Front Oncol. 2025-4-9

[4]
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.

Nat Cancer. 2025-4-3

[5]
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.

Nat Med. 2025-4

[6]
Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL.

Cancer Immunol Immunother. 2025-3-22

[7]
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.

Target Oncol. 2025-3

[8]
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.

Nat Rev Clin Oncol. 2025-4

[9]
Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies.

J Immunol Res. 2025-1-15

[10]
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.

Blood. 2025-4-3

本文引用的文献

[1]
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

J Clin Oncol. 2020-9-20

[2]
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.

Haematologica. 2021-4-1

[3]
Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.

Biol Blood Marrow Transplant. 2019-7-4

[4]
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Am J Hematol. 2019-8

[5]
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Lancet Oncol. 2018-12-2

[6]
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

N Engl J Med. 2017-12-28

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索